The diagnostic performances of three commercially available recombinant immunoblot assays (RIBAs) for anti-hepatitis C virus antibody were evaluated on 50 ORTHO-HCV RIBA-2 (RIBA-2)-indeterminate serum samples. Concordant transfusion hepatitis, 5 intravenous drug users, and 4 patients without known risk factors for HCV infection. The human immunodeficiency virus status was positive in 18 patients (15 hemophilic patients and 3 intravenous drug users). Twelve patients had elevated alanine aminotransferase (ALT) activity levels. Liver biopsy had been performed in nine cases. Cirrhosis was found in six cases, and chronic persistent hepatitis was found in three cases. HCV-indeterminate sera from blood donors were excluded from this study. All sera were stored at -30°C until use.
Since the development of the first enzyme-linked immunosorbent assay (ELISA) for the detection of anti-hepatitis C virus (HCV) antibody, the sensitivity and the specificity of subsequent assays (second and, recently, third generation) were progressively improved by the introduction of new HCV protein (1, 2, 7, 8) . Recombinant immunoblot assays (RIBAs) were widely used as confirmatory tests. However, approximately 10% of patients (6) with suspected viral liver disease have an indeterminate result in the ORTHO-HCV RIBA-2 (RIBA-2). In these cases, HCV RNA was detectable by reverse transcriptase PCR in 50% of the patients. The commercial availability of several new confirmatory tests for HCV antibody detection provides the opportunity to evaluate serum samples previously considered indeterminate by a second-generation ORTHO RIBA (ORTHO Diagnostic Systems, Chiron Corp., Emeryville, Calif.). These new assay systems use various mixtures of recombinant HCV antigens and synthetic peptides and can detect a broader range of anti-HCV antibodies. 2+  2+  2+  2+  3+  2+  3+  3+  2+  3+  3+  1+  2+  2+  1+  3+  3+  _  3+  2+  2+  2+  3+  1+  1+   3+  2+  2+  3+  1+  2+  3+  1+  2+  2+  3+  3+  2+  2+  3+  3+  2+  3+  3+   1+   2+  3+  3+  2+  2+  3+  2+  2+  3+  3+  3+  3+  2+  3+  3+  1+  2+  2+  2+  2+  3+  3+  3+  3+  1+  3+  3+  1+  3+  2+  2+  3+  3+  2+  3+  3+  1+   ±  2+  3+  4+  3+  2+  4+  3+  2+   1+   3+  3+  2+  3+  3+  2+  3+  2+  2+  3+  2+  2+  3+  2+  3+  3+  3+  2+  3+  2+  3+  3+   1+  3+  2+  4+  1+  4+  1+  3+  2+  4+  2+  4+  3+  4+  3+  3+  4+  1+  3+  2+  4+  4+  3+  4+  2+  4+  2+  4+  1+  4+  2+  4+  2+  4+  ±  3+  2+  4+  2+  4+  2+  4+  2+  4+  2+  4+  2+  4+  2+  4+  3+  4+  +  4+  2+  4+  2+  4+  3+  4+  4+  4+  4+  3+  4+  1+  4+  2+  4+  2+  4+  2+  4+  3+  3+  3+  4+  2+  4+  2+  4+   1+  1+  2+  3+  2+  4+  3+  2+  4+  3+   1+  1+  4+  2+  3+  4+ (Table  3) , 29 (58%) were classified as positive, 20 (40%) were indeterminate, and 1 (2%) was negative. All sera reactive to c33 (7 of 50 samples) or c22 (42 of 50 samples) in the RIBA-2 were also reactive to these antigens in the RIBA-3. Five of seven serum samples which displayed reactivity against c33 The ELISA OD readings of all tested serum samples were correlated with PCR positivity (P = 0.011); in contrast, no relationship was found between OD reading and confirmatory assay positivity, ALT elevation, and human immunodeficiency virus or immune status. The results of samples from the immunocompromised patients (n = 34) were analyzed separately and compared with those of samples from the immunocompetent patients (n = 15). As shown in Table 5 , there was no significant difference between the two groups.
DISCUSSION
This study shows clearly the good performance of the three confirmatory assays tested compared with that of the RIBA-2. As previously reported, the adjunction of either HCV-recombinant antigens or HCV-synthetic peptides has improved the specificity and sensitivity of new tests (1, 2) . Despite the fact 
